13 Nov 2026 Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
Manufacturing Work Addressing FDA CMC Information Requests Substantially Completed NDA Resubmission Expected Between December 2026 and January 2027 KANSAS CITY, Kan., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision
